<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7093024\results\search\testTrace\results.xml">
  <result pre="identified as novel inhibitors against IAV replication. A reporter virus-based" exact="infection" post="assay demonstrated that CHLA and CHLI exhibit no inhibitory"/>
  <result pre="Introduction Influenza vaccines and antiviral drugs are effective in preventing" exact="infection" post="or ameliorating disease severity (Vasileiou et al., 2017). However,"/>
  <result pre="anti-influenza therapies. The three clinically available classes of antivirals for" exact="treatment" post="and prevention of influenza infections are the viral ion"/>
  <result pre="product samples were screened for anti-IAV activity using a phenotypic" exact="screening" post="approach based on a recombinant IAV expressing Gaussia luciferase"/>
  <result pre="library of natural product samples was screened using a phenotypic" exact="screening" post="approach described previously (Zhao et al., 2019). Briefly, MDCK"/>
  <result pre="target to viral entry or genome replication steps, a one-cycle" exact="infection" post="inhibition assay was carried out using the reporter virus"/>
  <result pre="of Opti-MEM containing 2 Î¼g/mL of TPCKâ€&quot;trypsin, was used during" exact="infection" post="to avoid HA cleavage and infectious virus production. After"/>
  <result pre="natural product samples was prepared and screened using a phenotypic" exact="screening" post="approach based on a reporter influenza A PR8-PB2-Gluc virus"/>
  <result pre="a result, 12 hit samples were identified to inhibit IAV" exact="infection" post="(Supplementary Table S1). Among the most potent anti-IAV natural"/>
  <result pre="CHLA and CHLI on IAV replication, a reporter IAV-based one-cycle" exact="infection" post="assay was performed. Briefly, MDCK cells were infected by"/>
  <result pre="decreased expression of the reporter luciferase would be expected upon" exact="treatment" post="with inhibitors targeting virus entry or RNA replication. As"/>
  <result pre="IAV entry or RNA replication. FIGURE 3 Reporter luciferase-based one-cycle" exact="infection" post="inhibition assay. MDCK cells growing in 96-well plates were"/>
  <result pre="fetal bovine serum (FBS) were used as culture medium during" exact="infection" post="to avoid generation of infectious progeny viruses. At 24"/>
  <result pre="avoid generation of infectious progeny viruses. At 24 h post" exact="infection" post="(p.i.), Gluc expression was determined, and viral infectivities were"/>
  <result pre="assay. Briefly, infected cells were washed and cultured in an" exact="infection" post="medium for another 2 h, in the absence or"/>
  <result pre="of three independent experiments. Discussion In this study, a phenotypic" exact="screening" post="approach was initially used to evaluate 352 natural product"/>
  <result pre="Currently, four NA inhibitors are available for the prophylaxis and" exact="treatment" post="of influenza virus infections, including oseltamivir (Shobugawa et al.,"/>
  <result pre="catalytic pockets of target proteases or enzymes. However, in our" exact="screening" post="of anti-influenza activity described above, both of them showed"/>
  <result pre="AlameM. M.MassaadE.ZaraketH. (2016). Peramivir: a novel intravenous neuraminidase inhibitor for" exact="treatment" post="of acute influenza infections.Front. Microbiol.7:450. 10.3389/fmicb.2016.0045027065996 Alves GalvaoM. G.Rocha"/>
  <result pre="influenza A (H3N2) viruses in the 2005-2006 season and rapid" exact="detection" post="of amantadine-resistant influenza A (H3N2) viruses by MAMA-PCR.Jpn. J."/>
  <result pre="(2012). Clinical effectiveness of neuraminidase inhibitorsâ€&quot;oseltamivir, zanamivir, laninamivir, and peramivirâ€&quot;for" exact="treatment" post="of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study"/>
  <result pre="genes.Viruses10:679. 10.3390/v1012067930513620 ZhaoX.WangY.CuiQ.LiP.WangL.ChenZ.et al. (2019). A parallel phenotypic versus target-based" exact="screening" post="strategy for RNA-dependent RNA polymerase inhibitors of the influenza"/>
 </snippets>
</snippetsTree>
